Percheron Therapeutics (ASX:PER) has announced final results from its Phase I clinical trial of HMBD-002, a novel immunotherapy targeting multiple forms of advanced cancer, showing a strong safety profile and early signs of clinical activity. …
Percheron Therapeutics reports positive final data from early-phase trial of HMBD-002
October 7, 2025 Australian Biotech
Latest Video
New Stories
-
Company size shapes CEO pay trends in Australian health care and biotechnology
October 6, 2026 - - Latest News -
Young NZ cancer patients to get funded medicines no matter where they are treated
October 6, 2026 - - Latest News -
TGA turns to national security surveillance platform to police therapeutic goods compliance
October 6, 2026 - - Latest News -
CSL announces investment for share of Alentis rare kidney and liver candidate
October 6, 2026 - - Latest News -
TGA approves Roche's refillable eye implant for wet macular degeneration
October 5, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.34
October 2, 2026 - - Podcast -
Under the TGA's new rules, the safest story is one without the patient experience
October 2, 2026 - - Latest News